Last edition
News about "Dr Mark Williams"
Marvel Biosciences Reports Positive Preclinical Results for MB-204 in Fragile X Syndrome Study
Marvel Biosciences has reported positive preclinical results for its lead drug candidate, MB-204, in a Fragile X syndrome study conducted with the FRAXA Research Foundation. The findings further support the therapy's potential to treat autism spectrum disorder and related neurodevelopmental conditions.
Dr. Mark Williams | 06/08/2026 | By News Bureau
Marvel Biosciences Selects Novotech as CRO for MB-204 Phase-I Trial
Marvel Biosciences selects Novotech as CRO for its phase-I clinical trial of MB-204, a patented adenosine A2A antagonist, following successful cGMP synthesis and GLP toxicology studies.
Dr Mark Williams | 25/03/2026 | By News Bureau | 324
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy